MX2020008746A - 7-substituted sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of liver cancer. - Google Patents
7-substituted sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of liver cancer.Info
- Publication number
- MX2020008746A MX2020008746A MX2020008746A MX2020008746A MX2020008746A MX 2020008746 A MX2020008746 A MX 2020008746A MX 2020008746 A MX2020008746 A MX 2020008746A MX 2020008746 A MX2020008746 A MX 2020008746A MX 2020008746 A MX2020008746 A MX 2020008746A
- Authority
- MX
- Mexico
- Prior art keywords
- prophylaxis
- treatment
- liver cancer
- derivatives
- sup
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/24—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one nitrogen and one sulfur atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Abstract
The present invention relates to compounds of formula (I), wherein R<sup>1</sup>, R<sup>2</sup> and R<sup>3</sup> are as described herein, and their prodrugs or pharmaceutically acceptable salt, enantiomer or diastereomer thereof, for (use in) the treatment and/or prophylaxis of liver cancer.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2018077501 | 2018-02-28 | ||
| PCT/EP2019/054729 WO2019166432A1 (en) | 2018-02-28 | 2019-02-26 | 7-substituted sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of liver cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020008746A true MX2020008746A (en) | 2020-09-28 |
Family
ID=65685310
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020008746A MX2020008746A (en) | 2018-02-28 | 2019-02-26 | 7-substituted sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of liver cancer. |
Country Status (19)
| Country | Link |
|---|---|
| EP (1) | EP3758707A1 (en) |
| JP (1) | JP7089596B2 (en) |
| KR (1) | KR20200128414A (en) |
| CN (1) | CN111801100B (en) |
| AR (1) | AR114419A1 (en) |
| AU (1) | AU2019228654A1 (en) |
| BR (1) | BR112020016509A2 (en) |
| CA (1) | CA3091950A1 (en) |
| CL (1) | CL2020002139A1 (en) |
| CO (1) | CO2020010306A2 (en) |
| IL (1) | IL276817A (en) |
| MA (1) | MA52412A (en) |
| MX (1) | MX2020008746A (en) |
| PE (1) | PE20211456A1 (en) |
| PH (1) | PH12020551343A1 (en) |
| RU (1) | RU2020131012A (en) |
| SG (1) | SG11202008291XA (en) |
| TW (1) | TW202003518A (en) |
| WO (1) | WO2019166432A1 (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JOP20170169A1 (en) | 2016-08-29 | 2019-01-30 | Novartis Ag | Fused tricyclic pyridazinone compounds useful to treat orthomyxovirus infections |
| KR102409595B1 (en) | 2020-06-29 | 2022-06-17 | 한국과학기술연구원 | Novel purinone derivatives as protein kinase CSF-1R inhibitor |
| CN112420196A (en) * | 2020-11-20 | 2021-02-26 | 长沙市弘源心血管健康研究院 | Prediction method and system for survival rate of acute myocardial infarction patient within 5 years |
| WO2024013205A1 (en) * | 2022-07-14 | 2024-01-18 | F. Hoffmann-La Roche Ag | Phosphorylpurinone compounds for the treatment of cancer |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4189048B2 (en) | 1997-12-26 | 2008-12-03 | 大日本住友製薬株式会社 | Heterocyclic compounds |
| ES2623794T3 (en) | 2008-12-09 | 2017-07-12 | Gilead Sciences, Inc. | Intermediates for the preparation of toll receptor modulators |
| WO2010133885A1 (en) * | 2009-05-21 | 2010-11-25 | Astrazeneca Ab | Novel pyrimidine derivatives and their use in the treatment of cancer and further diseases |
| NO2491035T3 (en) * | 2009-10-22 | 2018-01-27 | ||
| US20110150836A1 (en) * | 2009-12-22 | 2011-06-23 | Gilead Sciences, Inc. | Methods of treating hbv and hcv infection |
| AU2011270701B2 (en) * | 2010-06-24 | 2015-05-14 | Alkermes Pharma Ireland Limited | Prodrugs of NH-acidic compounds: ester, carbonate, carbamate and phosphonate derivatives |
| BR112013002940A2 (en) * | 2010-08-13 | 2019-09-24 | Baylor Res Institute | new vaccine adjuvants based on targeting adjuvants for antibodies directly to antigen presenting cells |
| UA120450C2 (en) * | 2015-05-08 | 2019-12-10 | Ф. Хоффманн-Ля Рош Аг | Novel sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of virus infection |
| MA44334A (en) | 2015-10-29 | 2018-09-05 | Novartis Ag | ANTIBODY CONJUGATES INCLUDING A TOLL-TYPE RECEPTOR AGONIST |
| NZ750604A (en) * | 2016-08-29 | 2024-02-23 | Hoffmann La Roche | Novel 7-substituted sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of virus infection |
| ES2894605T3 (en) * | 2016-09-13 | 2022-02-15 | Hoffmann La Roche | Combination therapy with a TLR7 agonist and an HBV capsid assembly inhibitor |
-
2019
- 2019-02-26 SG SG11202008291XA patent/SG11202008291XA/en unknown
- 2019-02-26 JP JP2020544794A patent/JP7089596B2/en active Active
- 2019-02-26 RU RU2020131012A patent/RU2020131012A/en unknown
- 2019-02-26 BR BR112020016509-3A patent/BR112020016509A2/en not_active Application Discontinuation
- 2019-02-26 CA CA3091950A patent/CA3091950A1/en active Pending
- 2019-02-26 EP EP19708981.6A patent/EP3758707A1/en active Pending
- 2019-02-26 MX MX2020008746A patent/MX2020008746A/en unknown
- 2019-02-26 AU AU2019228654A patent/AU2019228654A1/en not_active Abandoned
- 2019-02-26 KR KR1020207027935A patent/KR20200128414A/en unknown
- 2019-02-26 MA MA052412A patent/MA52412A/en unknown
- 2019-02-26 WO PCT/EP2019/054729 patent/WO2019166432A1/en unknown
- 2019-02-26 CN CN201980015912.7A patent/CN111801100B/en active Active
- 2019-02-26 PE PE2020001228A patent/PE20211456A1/en unknown
- 2019-02-27 TW TW108106752A patent/TW202003518A/en unknown
- 2019-02-28 AR ARP190100505A patent/AR114419A1/en unknown
-
2020
- 2020-08-19 IL IL276817A patent/IL276817A/en unknown
- 2020-08-19 CL CL2020002139A patent/CL2020002139A1/en unknown
- 2020-08-21 CO CONC2020/0010306A patent/CO2020010306A2/en unknown
- 2020-08-27 PH PH12020551343A patent/PH12020551343A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| SG11202008291XA (en) | 2020-09-29 |
| EP3758707A1 (en) | 2021-01-06 |
| CN111801100B (en) | 2023-10-24 |
| BR112020016509A2 (en) | 2020-12-15 |
| CN111801100A (en) | 2020-10-20 |
| CA3091950A1 (en) | 2019-09-06 |
| CL2020002139A1 (en) | 2021-01-04 |
| AR114419A1 (en) | 2020-09-02 |
| JP7089596B2 (en) | 2022-06-22 |
| JP2021514972A (en) | 2021-06-17 |
| RU2020131012A (en) | 2022-03-28 |
| AU2019228654A1 (en) | 2020-09-03 |
| KR20200128414A (en) | 2020-11-12 |
| IL276817A (en) | 2020-10-29 |
| WO2019166432A1 (en) | 2019-09-06 |
| CO2020010306A2 (en) | 2020-08-31 |
| PH12020551343A1 (en) | 2021-06-21 |
| PE20211456A1 (en) | 2021-08-05 |
| MA52412A (en) | 2021-06-02 |
| TW202003518A (en) | 2020-01-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2023010806A (en) | Substituted 1,2-dihydro-3h-pyrazolo[3,4-d]pyrimidin-3-ones. | |
| PH12018502102A1 (en) | Pyrrolotriazine compounds as tam inhibitors | |
| MX2016017030A (en) | Mnk inhibitors and methods related thereto. | |
| PH12017501061B1 (en) | 3-substituted 5-amino-6h-thiazolo[4,5-d]pyrimidine-2,7-dione compounds for the treatment and prophylaxis of virus infection | |
| MX2023001876A (en) | Rapamycin derivatives. | |
| MX2021006902A (en) | 7-substituted sulfonimidoylpurinone compounds for the treatment and prophylaxis of virus infection. | |
| MX2020001235A (en) | 1, 2 - dihydro- 3h- pyrazolo [3, 4 - d] pyrimidin -3 - one analogs. | |
| MX2021013075A (en) | Oxysterols and methods of use thereof. | |
| GEP20207105B (en) | 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2yl carbamate derivatives as magl inhibitors | |
| TN2016000501A1 (en) | Pyrrolidine-2,5-dione derivatives, pharmaceutical compositions and methods for use as ido1 inhibitors. | |
| MX2020008746A (en) | 7-substituted sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of liver cancer. | |
| MY196749A (en) | Eif4a-inhibiting compounds and methods related thereto | |
| EP3693369A3 (en) | Bromodomain inhibitors | |
| EP4316591A3 (en) | Oxysterols and methods of use thereof | |
| MX2020010690A (en) | Oxysterols and methods of use thereof. | |
| PH12017502009A1 (en) | Novel sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of virus infection | |
| PH12019550140A1 (en) | Piperidine-substituted mnk inhibitors and methods related thereto | |
| MX2020012827A (en) | Tetrahydro-1 h-pyrazino[2,1 -ajisoindolylquinoline compounds for the treatment of autoimmune disease. | |
| TN2017000485A1 (en) | Tricyclic compounds and their use as phosphodiesterase inhibitors | |
| MX2021012105A (en) | Pyrrole compounds. | |
| TN2017000342A1 (en) | Novel cyclopropabenzofuranyl pyridopyrazinediones | |
| TN2016000459A1 (en) | Cycloalkyl-linked diheterocycle derivatives. | |
| MX2019011558A (en) | Novel substituted n'-hydroxycarbamimidoyl-1,2,5-oxadiazole compounds as indoleamine 2,3-dioxygenase (ido) inhibitors. | |
| MX2021014458A (en) | Tricyclic compounds. | |
| WO2016112304A8 (en) | Furoquinolinediones as inhibitors of tdp2 |